Amanda Corbel
Manager, Communications Office
Email amanda.corbel@nih.gov or call 301-228-4489 for all media related questions.
Vertical RAS Pathway Inhibition Creates a Ferroptosis-Prone State in Pancreatic Cancer
KRAS pathway inhibition rewires PDAC metabolism, increasing oxidative stress—and revealing a new vulnerability: ferroptosis as a strategy to overcome resistance.POSTED: 4/13/2026
Vaccine set for wider use against mosquito-borne chikungunya
The vaccine Vimkunya may become a bigger player in global health following a series of adverse event reports linked to the only other available vaccine for chikungunya.POSTED: 3/25/2026
Research team identifies possible new targets for liver cancer therapy
New research may have found a stable population of cells that could serve as a bull's eye for effective liver cancer therapy.POSTED: 3/19/2026
KRAS primes the road for WNT-driven tumour initiation
New research reveals that activating KRAS mutations can quietly expand in normal colon tissue and prime cells for cancer, overturning the long‑held idea that APC loss must always be the first step in colorectal tumorigenesis.POSTED: 3/16/2026
Women in Science Speak builds community for fifth straight year
Another Women in Science Speak event connected professionals and students on topics surrounding women in STEM, mentorship, and professional development.POSTED: 3/3/2026
Cancer Moonshot Biobank surpasses 1,000 enrollments
Exceeding its goal, the Biobank promises to enable cancer research aimed at understanding drug sensitivity and resistance.POSTED: 2/20/2026
A new way to break drug resistance in KRAS-mutant lung cancer: Restoring PP2A to re-sensitize tumors to RAS/MAPK inhibitors
Resistance to RAS/MAPK inhibitors isn’t just about runaway kinases—it’s about silenced phosphatases. In this JCI study, Dr. Goutham Narla shows that KRAS-mutant tumors evade therapy by disabling PP2A, and that pharmacologically restoring phosphatase activity rewires signaling, blocks resistance, and delivers durable responses.POSTED: 2/16/2026
Scientists report new method for finding a tuberculosis vaccine
A multi-institutional team used a novel approach for identifying all possible vaccine targets against the disease-causing Mycobacterium tuberculosis.POSTED: 2/4/2026
Multi-laboratory study demonstrates high agreement among molecular tumor tests
A study of 26 U.S. laboratories reinforced confidence in next-generation sequencing tumor tests' reliability for precision cancer care. POSTED: 1/26/2026
Exosomes in personalized medicine for pancreatic cancer
Nature’s own delivery system meets precision oncology: the decade-long journey of engineered exosomes to a first-in-human KRAS trial.POSTED: 1/12/2026
Looking for more?
Explore our scientific publications
Our researchers publish hundreds of papers each year in various peer-reviewed journals, including Science, Nature, and The New England Journal of Medicine.